Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation
Autor: | Sandro Pasquali, Monica Tortoreto, Calogero Lauricella, Gianpaolo Dagrada, Alessandro Gronchi, Roberta Sanfilippo, Silvia Stacchiotti, Marta Barisella, Chiara Colombo, Stefano Percio, Valentina Zuco, Mrinal M. Gounder, Paolo G. Casali, Rihan El Bezawy, Silvia Brich, Nadia Zaffaroni, Angelo Paolo Dei Tos |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
0301 basic medicine Cancer Research Survivin Down-Regulation Mice Nude Selinexor Apoptosis lcsh:RC254-282 Dedifferentiated liposarcoma Doxorubicin PDX Primary cell culture XPO1 Mice Random Allocation 03 medical and health sciences 0302 clinical medicine HMGA2 Downregulation and upregulation medicine Animals Humans STAT3 Nuclear export signal Cell Nucleus Antibiotics Antineoplastic biology Chemistry Research Liposarcoma Cell Dedifferentiation Triazoles lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Xenograft Model Antitumor Assays Hydrazines 030104 developmental biology Oncology 030220 oncology & carcinogenesis biology.protein Cancer research Mdm2 Tumor Suppressor Protein p53 medicine.drug |
Zdroj: | Journal of Experimental & Clinical Cancer Research : CR Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-12 (2021) |
ISSN: | 1756-9966 |
DOI: | 10.1186/s13046-021-01886-x |
Popis: | Background Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53. MDM2 ubiquitination of p53 facilitates its XPO1-mediated nuclear export, thus limiting p53 tumor suppressor functions. Consequently, nuclear export is a rational target in DDLPS. We directly compared the antitumor activity of the first-in class XPO1 inhibitor selinexor and doxorubicin, the standard front-line therapy in sarcomas, in DDLPS patient-derived xenografts (PDXs) and primary cell lines. Methods Drug activity was assessed in three PDXs (and two corresponding cell lines) established from the dedifferentiated component of primary untreated retroperitoneal DDLPS with myogenic (N = 2) and rhabdomyoblastic (N = 1) differentiation from patients who underwent surgery. These models were marked by amplification of MDM2, CDK4 and HMGA2 genes. Results Selinexor was moderately active in the three PDXs but achieved greater tumor response compared to doxorubicin (maximum tumor volume inhibition: 46–80 % vs. 37–60 %). The PDX harboring rhabdomyoblastic dedifferentiation showed the highest sensitivity to both agents. PDX response to selinexor and doxorubicin was not associated with the extent of MDM2 and CDK4 gene amplification. Interestingly, the most chemosensitive PDX model showed the lowest extent of HMGA2 amplification. Selinexor was also more efficient than doxorubicinin in inducing an apoptotic response in PDXs and cell lines. Consistently, an increased nuclear accumulation of p53 was seen in all selinexor-treated models. In addition, a time-dependent decrease of survivin expression, with an almost complete abrogation of the cytoplasmic anti-apoptotic pool of this protein, was observed as a consequence of the decreased acetylation/activation of STAT3 and the increased ubiquitination of nuclear survivin. Conclusions Selinexor showed a moderate antitumor activity in three DDLPS PDXs, which was, however, consistently higher than doxorubicin across all different models regardless the extent of MDM2 amplification and the histological differentiation. The depletion of survivin protein seems to significantly contribute to the induction of apoptosis through which selinexor exerts its antitumor activity. |
Databáze: | OpenAIRE |
Externí odkaz: |